
    
      TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085
      contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl
      docosahexaenoic acid (DHA-E)).

      This is a phase 3, open-label, randomized study to evaluate the efficacy and safety of
      TAK-085. In addition, EPA-E is also administered for 52 weeks for reference to evaluate the
      safety of TAK-085 in participants with hypertriglyceridemia who are undergoing lifestyle
      modification.

      The study period is a total of 56 weeks, comprised of a 4- week screening period and 52 weeks
      of treatment.
    
  